Mersana Therapeutics (MRSN) Price & Analysis

Compare

660 Followers

MRSN Stock Chart & Stats

Day’s Range― - ―

52-Week Range$5.21 - $70.75

Previous CloseN/A

Volume429.52K

Average Volume (3M)123.29K

Market Cap

$38.18M

Enterprise Value-$19.93M

Total Cash (Recent Filing)$76.97M

Total Debt (Recent Filing)$20.62M

Price to Earnings (P/E)―

Beta2.79

Next Earnings

Nov 11, 2025

EPS Estimate

-1.54

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-4.87

Shares Outstanding4,990,692

10 Day Avg. Volume130,073

30 Day Avg. Volume123,288

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap-0.52

Enterprise Value/Revenue-0.57

Enterprise Value/Gross Profit-0.58

Enterprise Value/Ebitda0.29

Forecast

1Y Price Target

$35.40

Price Target Upside362.75% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering7

Bulls Say, Bears Say

Bulls Say

Clinical TrialsThe data presented from dose escalation and backfill cohorts from the Phase I trial of Emi-Le was viewed as incrementally positive for its path forward.

Financial MilestonesAchievement of a $15M development milestone from GSK for the XMT-2056 program was announced.

Bears Say

Financial ConstraintsCompany has approximately 0.8 years of cash left, indicating potential financial constraints.

Financial PerformanceMersana reported a net loss of $24.3 million, which was slightly worse than the estimate of a loss of $22.5 million and consensus estimates of a loss of $19.9 million.

Mersana Therapeutics News

Mersana Therapeutics price target adjusted to $36 at Truist after reverse split

Truist analyst Asthika Goonewardene lowered the firm’s price target on Mersana Therapeutics (MRSN) to $36 from $250 and...

14d ago

MRSN

Mersana Therapeutics price target adjusted to $17 at BTIG after reverse split

BTIG adjusted the firm’s price target on Mersana Therapeutics (MRSN) to $17 from $6 and keeps a Buy...

15d ago

MRSN

Mersana Therapeutics reports Q2 EPS ($4.87), consensus ($4.25)

Reports Q2 revenue $3.056M, consensus $6.06M. “During the second quarter, we were excited to have Emi-Le clinical data...

15d ago

MRSN

Mersana Therapeutics Positioned Favorably with Promising Developments and Strategic Adjustments Supporting Buy Rating

In a report released on August 13, Charles Zhu from LifeSci Capital maintained a Buy rating on Mersana...

13d ago

MRSN

Mersana Therapeutics Faces Financial Strain Amid U.S. Tariff Uncertainties

Mersana Therapeutics (MRSN) has disclosed a new risk, in the Capital Markets category. Mersana Therapeutics faces significant business...

15d ago

MRSN

Mersana Therapeutics Reports Q2 2025 Financial Results

Mersana Therapeutics ( ($MRSN) ) has released its Q2 earnings. Here is a breakdown of the information Mersana...

15d ago

MRSN

Promising Progress and Strategic Focus Drive Buy Rating for Mersana Therapeutics

TD Cowen analyst Tara Bancroft has maintained their bullish stance on MRSN stock, giving a Buy rating today....

15d ago

MRSN

MRSN Upcoming Earnings Report: What to Expect?

Mersana Therapeutics (MRSN) is scheduled to report 2nd quarter earnings on 08/13/2025, before the market opens. Regarding Q2...

18d ago

MRSN

Upcoming Stock Splits This Week (July 28 to August 1) – Stay Invested

These are the upcoming stock splits for the week of July 28 to August 1, based on TipRanks’ Stock...

1M ago

AGRI

AIHS

Mersana Therapeutics trading halted, news pending

19:50 EDT Mersana Therapeutics (MRSN) trading halted, news pending Published first on TheFly – the ultimate source for...

1M ago

MRSN

Mersana Therapeutics Announces Reverse Stock Split

Mersana Therapeutics ( ($MRSN) ) just unveiled an update. On July 24, 2025, Mersana Therapeutics announced a 1-for-25...

1M ago

MRSN

Mersana Therapeutics announces 1-for-25 reverse stock split

Mersana Therapeutics (MRSN) announced that it will implement a 1-for-25 reverse stock split of the issued shares of...

1M ago

MRSN

Mersana Therapeutics’ XMT-1660 Study: A Potential Game-Changer in Cancer Treatment

Mersana Therapeutics (($MRSN)) announced an update on their ongoing clinical study. Study Overview: Mersana Therapeutics is conducting a...

1M ago

MRSN

Mersana Therapeutics Advances HER2-Targeted Cancer Therapy with XMT-2056 Study

Mersana Therapeutics (($MRSN)) announced an update on their ongoing clinical study. Study Overview: Mersana Therapeutics is conducting a...

2M ago

MRSN

MRSN FAQ

What was Mersana Therapeutics Inc’s price range in the past 12 months?

Mersana Therapeutics Inc lowest stock price was $5.21 and its highest was $70.75 in the past 12 months.

What is Mersana Therapeutics Inc’s market cap?

Mersana Therapeutics Inc’s market cap is $38.18M.

When is Mersana Therapeutics Inc’s upcoming earnings report date?

Mersana Therapeutics Inc’s upcoming earnings report date is Nov 11, 2025 which is in 75 days.

How were Mersana Therapeutics Inc’s earnings last quarter?

Mersana Therapeutics Inc released its earnings results on Aug 13, 2025. The company reported -$4.87 earnings per share for the quarter, missing the consensus estimate of -$3.865 by -$1.005.

Is Mersana Therapeutics Inc overvalued?

According to Wall Street analysts Mersana Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Mersana Therapeutics Inc pay dividends?

Mersana Therapeutics Inc does not currently pay dividends.

What is Mersana Therapeutics Inc’s EPS estimate?

Mersana Therapeutics Inc’s EPS estimate is -1.54.

How many shares outstanding does Mersana Therapeutics Inc have?

Mersana Therapeutics Inc has 4,990,692 shares outstanding.

What happened to Mersana Therapeutics Inc’s price movement after its last earnings report?

Mersana Therapeutics Inc reported an EPS of -$4.87 in its last earnings report, missing expectations of -$3.865. Following the earnings report the stock price went up 12.191%.

Which hedge fund is a major shareholder of Mersana Therapeutics Inc?

Currently, no hedge funds are holding shares in MRSN

Mersana Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

-505.14%

Trailing 12-Months

Asset Growth

-52.79%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Mersana Therapeutics Inc

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development candidate. It has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.

Mersana Therapeutics (MRSN) Earnings & Revenues

Historic Earnings Reports

MRSN Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

The call highlighted significant progress in clinical trials and milestone achievements, especially in the Emi-Le and XMT-2056 programs. However, challenges remain with proteinuria management and modest revenue growth, balanced by a stable financial outlook.View all MRSN earnings summaries

MRSN Stock 12 Month Forecast

Average Price Target

$35.40

▲(362.75% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","58":"$58","18.25":"$18.25","31.5":"$31.5","44.75":"$44.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":50,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$50.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":35.4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$35.40</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$17.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,18.25,31.5,44.75,58],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.6,9.938461538461539,13.276923076923076,16.615384615384613,19.95384615384615,23.292307692307688,26.630769230769232,29.96923076923077,33.30769230769231,36.646153846153844,39.98461538461538,43.32307692307692,46.66153846153846,{"y":50,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.6,8.815384615384614,11.03076923076923,13.246153846153845,15.46153846153846,17.676923076923075,19.89230769230769,22.107692307692304,24.32307692307692,26.538461538461533,28.753846153846148,30.969230769230762,33.184615384615384,{"y":35.4,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.6,7.3999999999999995,8.2,9,9.8,10.6,11.4,12.2,13,13.8,14.6,15.4,16.200000000000003,{"y":17,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":49.25,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.5,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.5,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.5,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.75,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.22,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.08,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.36,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.35,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.98,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.6,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >